- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02471989
FODMAPs and Refractory GERD (EFFORR)
December 17, 2015 updated by: University Hospital, Bordeaux
Randomized Controlled Study of Low-FODMAP Diet in Patients With GERD Refractory to Protons Pump Inhibitors
The aim of this study is to determine the effects of a low Fermentescible Oligosaccharides Disaccharides Monosaccharides and Polyols (FODMAP) diet in patients with documented refractory GERD on proton pump inhibitor (PPI) therapy.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Colonic fermentation has been shown to influence oeso-gastric motility : increased gastric relaxation, increased rate of lower esophageal sphincter relaxation.
Experimental increased colonic fermentation (FOS in diet) increase the occurrence of reflux events in patients with GERD.
The aim of this study is to compare the low-FODMAP diet and classical GERD dietary recommendations (avoid fatty meals, head of bed elevation etc..) in patients with refractory GERD symptoms.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Frank ZERBIB, Prof
- Phone Number: +33 (0)556795806
- Email: frank.zerbib@chu-bordeaux.fr
Study Contact Backup
- Name: Amandine MOURTHE
- Phone Number: +33 (0)557820624
- Email: amandine.mourthe@chu-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France, 33075
- Recruiting
- Hépato-Gastroentérologie et oncologie digestive,
-
Contact:
- Frank ZERBIB
- Phone Number: +33 (0)556795806
- Email: frank.zerbib@chu-bordeaux.fr
-
Contact:
- Phone Number: +33 (0)557820624
- Email: amandine.mourthe@chu-bordeaux.fr
-
Colombes, France, 92700
- Not yet recruiting
- Gastroentérologie
-
Contact:
- Jean-Marc SABATE, Prof
- Email: jean-marc.sabate@lmr.aphp.fr
-
Lyon, France, 69437
- Not yet recruiting
- Explorations fonctionnelles
-
Contact:
- Sabine ROMAN, MD
- Email: sabine.roman@chu-lyon.fr
-
Nantes, France, 44093
- Not yet recruiting
- Gastroentérologie
-
Contact:
- Stanislas Bruley des Varannes, Prof
- Email: stanislas.bruleydesvarannes@chu-nantes.fr
-
Rennes, France, 35033
- Not yet recruiting
- Explorations fonctionnelles Digestives
-
Contact:
- Alain ROPERT, MD
- Email: alain.ropert@chu-rennes.fr
-
Rouen, France, 76031
- Not yet recruiting
- Gastroentérologie
-
Contact:
- Philippe Ducrotté, Prof
- Email: philippe.ducrotte@chu-rouen.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 18
- Affiliation to French Social Security
- Informed written consent
- RDQ score > 3
- Abnormal pH-impedance monitoring on PPI twice daily (since 3 months) according to normal values published by Zerbib et al (CGH 2013)
Exclusion Criteria:
- Pregnancy or breast feeding
- Women of childbearing potential without an effective method of contraception
- Person under guardianship
- History of thoracic of abdominal surgery (excepted appendectomy and cholecystectomy)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-FODMAP diet
FOS in diet
|
|
Active Comparator: Classical GERD diet
avoid fatty meals, head of bed elevation...
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients with clinical remission as defined by a RDQ score ≤ 3
Time Frame: at Week 4 of diet
|
at Week 4 of diet
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Between-group comparison of efficacy
Time Frame: at Week 4 of diet
|
This measure is a composite with :
|
at Week 4 of diet
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Frank ZERBIB, Prof, University Hospital, Bordeaux
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Anticipated)
December 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
June 5, 2015
First Submitted That Met QC Criteria
June 10, 2015
First Posted (Estimate)
June 15, 2015
Study Record Updates
Last Update Posted (Estimate)
December 18, 2015
Last Update Submitted That Met QC Criteria
December 17, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2015/02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastro-esophageal Reflux Disease (GERD)
-
Mayo ClinicWithdrawnGastro-esophageal Reflux Disease (GERD)United States
-
Reckitt Benckiser Healthcare (UK) LimitedCompletedGastro-esophageal Reflux Disease (GERD)China
-
Reckitt Benckiser Healthcare (UK) LimitedTerminatedGastro-esophageal Reflux Disease (GERD)China
-
Janssen-Cilag International NVCompletedGastroesophageal Reflux Disease | GERD | Gastro-oesophageal Reflux | Gastro-Esophageal Reflux | Esophageal Reflux
-
Torax Medical IncorporatedCompletedGastroesophageal Reflux | Gastro Esophageal Reflux | GERDItaly, Austria, Germany, United Kingdom
-
St. Luke's Medical Center, PhilippinesTerminatedGastro Esophageal Reflux | GERDPhilippines
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
Stanford UniversityWithdrawnDysphagia | Scleroderma | GERD - Gastro-Esophageal Reflux DiseaseUnited States
-
Evangelic Hospital Kalk CologneCompletedAnxiety Disorders | GERD - Gastro-Esophageal Reflux DiseaseGermany
Clinical Trials on Low-FODMAP diet
-
Ashok TutejaUnited States Department of DefenseUnknown
-
Cantonal Hospital of St. GallenCompletedIBS - Irritable Bowel Syndrome
-
Beth Israel Deaconess Medical CenterEnrolling by invitation
-
Ohio State UniversityCompletedAutism Spectrum DisorderUnited States
-
University of NottinghamKing's College LondonCompletedIrritable Bowel SyndromeUnited Kingdom
-
Northwestern UniversityWithdrawn
-
Taipei Veterans General Hospital, TaiwanNot yet recruitingIrritable Bowel Syndrome
-
Universitaire Ziekenhuizen KU LeuvenCompletedFunctional Dyspepsia | FODMAP DietBelgium
-
Oslo University HospitalActive, not recruitingIrritable Bowel Syndrome | Diet Modification | Celiac Disease | Gluten SensitivityNorway
-
Medical University of WarsawNutricia FoundationUnknown